YI.US
Ribo does biotech

Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of selling drugs to pharmacies and medical institutions fell by 6.2%. Its much smaller business of selling drugs directly to consumers also fell 9.6% for the quarter year-on-year.

The company’s operating costs and expenses fell by a similar 6.3% to 3.2 billion yuan from 3.4 billion yuan in the year-ago period. As a result, 111 Inc. reported positive income from operations of $100,000 for the quarter. But its net loss widened to 19.5 million yuan from 14 million yuan a year earlier.

The company’s shares fell 6.2% on Wednesday after the report’s publication. The stock is down 40% over the last six months.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

World’s leading plastic planters maker Consumer Solution seeks Hong Kong listing

Planter giant CSW extends roots to Hong Kong

The world’s largest producer of decorative plastic planters has applied for an IPO, boasting a mostly U.S. clientele that includes retailing giants like Lowe’s, Walmart and Costco Key Takeaways: CSW…